Earnings ·
Orthofix raises full-year net sales guidance to $845M-$855M as Q2 revenue grows 4% to $210.9M
OFIXOrthofix Medical Inc.
Orthofix Medical Inc. reported second quarter 2026 financial results for the period ended June 30, 2026, announcing a net loss of $15.8 million and non-GAAP adjusted EBITDA of $20.1 million. Reported net sales reached $210.9 million, reflecting 4% growth on a reported basis and 5% growth on a pro forma constant currency basis compared to the prior year period. The company raised its full-year 2026 guidance, increasing expected net sales to a range of $845 million to $855 million and adjusted EBITDA to $95 million to $98 million. Orthofix Medical Inc. operates in the medical technology industry, specializing in musculoskeletal solutions including spinal implants, biologics, limb reconstruction systems, and bone growth therapies.